Cutaneous sarcoidosis successfully treated with alefacept

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Sarcoidosis is a multi-system granulomatous disease with unknown causes.
• Alefacept is a biologic fusion protein that inhibits T-cell activation and induces T-cell apoptosis.
• Understanding sarcoidosis immunology is key to developing new treatments.

Observation:

• A 46-year-old patient presented with recalcitrant lupus pernio, a form of cutaneous sarcoidosis.
• The patient received intramuscular injections of alefacept.
• Treatment involved T-cell inhibition via alefacept.

Findings:

• Modest clinical improvement was observed after 8 weeks of alefacept treatment.
• The patient's lupus pernio showed signs of response to the therapy.
• Alefacept demonstrated efficacy in this case report.

Implications:

• This case provides evidence for using biologic agents targeting T-lymphocyte activation in sarcoidosis treatment.
• Alefacept may be a viable option for recalcitrant cutaneous sarcoidosis.
• Further research into T-cell targeted therapies for sarcoidosis is warranted.